Fundsmith LLP Sells 1,307 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fundsmith LLP lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,662,855 shares of the company's stock after selling 1,307 shares during the period. IDEXX Laboratories makes up approximately 4.7% of Fundsmith LLP's holdings, making the stock its 10th biggest position. Fundsmith LLP owned about 3.25% of IDEXX Laboratories worth $1,100,931,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. Deutsche Bank AG increased its stake in shares of IDEXX Laboratories by 17.9% in the fourth quarter. Deutsche Bank AG now owns 357,479 shares of the company's stock worth $147,796,000 after purchasing an additional 54,360 shares during the period. Colonial Trust Co SC increased its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the period. Crestline Management LP bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $1,462,000. Centiva Capital LP increased its stake in shares of IDEXX Laboratories by 286.6% in the fourth quarter. Centiva Capital LP now owns 1,616 shares of the company's stock worth $668,000 after purchasing an additional 1,198 shares during the period. Finally, Brevan Howard Capital Management LP increased its stake in shares of IDEXX Laboratories by 1,228.1% in the fourth quarter. Brevan Howard Capital Management LP now owns 8,513 shares of the company's stock worth $3,520,000 after purchasing an additional 7,872 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX traded up $1.72 on Friday, hitting $491.70. 668,502 shares of the stock traded hands, compared to its average volume of 649,765. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $39.54 billion, a PE ratio of 46.08, a P/E/G ratio of 3.41 and a beta of 1.52. The business has a fifty day moving average price of $423.31 and a two-hundred day moving average price of $429.00.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.71 earnings per share. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on IDXX shares. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Morgan Stanley boosted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Finally, Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $524.75.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.